[1]李悦,卢成志.经皮去肾神经术:最新证据与患者筛选[J].心血管病学进展,2024,(3):211.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.005]
 LI Yue,LU Chengzhi.Renal Denervation:Latest Evidence and Patient Selection[J].Advances in Cardiovascular Diseases,2024,(3):211.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.005]
点击复制

经皮去肾神经术:最新证据与患者筛选()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年3期
页码:
211
栏目:
主题综述
出版日期:
2024-03-25

文章信息/Info

Title:
Renal Denervation:Latest Evidence and Patient Selection
作者:
李悦卢成志
(天津市第一中心医院心内科,天津 300000)
Author(s):
LI YueLU Chengzhi
(Tianjin First Central Hospital,Tianjin 300000,China)
关键词:
高血压交感神经系统经皮去肾神经术
Keywords:
HypertensionSympathetic nervous systemRenal denervation
DOI:
10.16806/j.cnki.issn.1004-3934.2024.03.005
摘要:
尽管有许多药物和非药物治疗可降低血压,但难治性高血压仍是一个重要的健康问题。经皮去肾神经术(RDN)已成为有发展前景、临床证据最多的用于改善血压、提高血压控制率的器械治疗方法。现总结目前RDN治疗高血压的机制,同时总结了关于RDN的多项随机假手术对照的临床研究和优化患者选择。
Abstract:
Despite the existence of numerous pharmacological and non-pharmacological interventions for lowering blood pressure,refractory hypertension persists as a significant health concern. Renal denervation(RDN) has become a promising and clinically proven instrument therapy method for improving blood pressure and increasing blood pressure control. This review summarizes the current understanding of the mechanisms behind RDN in treating hypertension and provide s an overview of several randomized sham-controlled clinical studies on RDN,as well as optimization of patient selection.

参考文献/References:

[1].DiBona GF. Sympathetic nervous system and the kidney in hypertension[J]. Curr Opin Nephrol Hypertens,2002,11(2):197-200.
[2].Johns EJ,Kopp UC,DiBona GF. Neural control of renal function[J]. Compr Physiol,2011,1(2):731-767.
[3].Smithwick RH,Porell WJ,Whitelaw GP. Diagnosis of hypertension of adrenal and renal origin[J]. JAMA ,1960,174:127-132.
[4].Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[5].Fadl Elmula FE,Hoffmann P,Larstorp AC,et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension[J]. Hypertension,2014,63(5):991-999.
[6].Jin Y,Persu A,Staessen JA. Renal denervation in the management of resistant hypertension:current evidence and perspectives[J]. Curr Opin Nephrol Hypertens,2013,22(5):511-518.
[7].Persu A,Renkin J,Asayama K,et al. Renal denervation in treatment-resistant hypertension:the need for restraint and more and better evidence[J]. Expert Rev Cardiovasc Ther,2013,11(6):739-749.
[8].Tam GM,Yan BP,Shetty SV,et al. Transcatheter renal artery sympathetic denervation for resistant hypertension:an old paradigm revisited[J]. Int J Cardiol,2013,164(3):277-281.
[9].Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[10].Esler M,Lambert G,Jennings G. Regional norepinephrine turnover in human hypertension[J]. Clin Exp Hypertens A,1989,11(suppl 1):75-89.
[11].Grassi G,Cattaneo BM,Seravalle G,et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension[J]. Hypertension,1998,31(1):68-72.
[12].Grassi G,Seravalle G,Dell’Oro R,et al. Adrenergic and reflex abnormalities in obesity-related hypertension[J]. Hypertension,2000,36(4):538-542.
[13].Papin E,Ambard L. Resection of the nerves of the kidney for nephralgia and small hydronephroses[J]. J Urol,1924,11:337-349.
[14].Adson A,McCraig W,Brown G. Surgery in its relation to hypertension[J]. Surg Gynecol Obstet,1936,62:314-331.
[15].Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009,373(9671):1275-1281.
[16].Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.
[17].Kandzari DE,B?hm M,Mahfoud F,et al. E?ect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355.
[18].B?hm M,Kario K,Kandzari DE,et al. E?cacy of catheterbased renal denervation in the absence of antihypertensive medications(SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised,sham-controlled trial[J]. Lancet,2020,395(10234):1444-1451.
[19].Kario K,Yokoi Y,Okamura K,et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension:the randomized,controlled REQUIRE trial[J]. Hypertens Res,2022,45(2):221-231.
[20].Wang J,Sun N,Ge J,et al. Rationale and design of sympathetic mapping/ablation of renal nerves trial(SMART) for the treatment of hypertension:a prospective,multicenter,single-blind,randomized and sham procedure-controlled study[J]. J Cardiovasc Transl Res,2023,16(2):358-370.
[21].Wang L,Li C,Li Z,et al. Ten-year follow-up of very-high risk hypertensive patients undergoing renal sympathetic denervation[J]. J Hypertens,2023,Dec 21.DOI:10.1097/HJH.0000000000003650.?Online ahead of print.
[22].Wilder J. Basimetric approach(law of initial value) to biological rhythms[J]. Ann N Y Acad Sci,1962,98:1211-1220.
[23].施仲伟,冯颖青,林金秀,等. 高血压患者心率管理中国专家共识[J]. 中国医学前沿杂志电子版,2017,9(8):8.
[24].B?hm M,Tsioufis K,Kandzari DE,et al. Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension[J]. J Am Coll Cardiol,2021,78(10):1028-1038.
[25].Mahfoud F,Townsend RR,Kandzari DE,et al. Changes in plasma renin activity after renal artery sympathetic denervation[J]. J Am Coll Cardiol,2021,77(23):2909-2919.
[26].王丽,卢成志,张欣,等. 经导管去肾交感神经术2年随访结果:更适合中青年顽固性高血压患者?[J]. 中华高血压杂志,2015,23(12):1200.
[27].Sata Y,Hering D,Head GA,et al. Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation[J]. J Hypertens,2018,36(6):1414-1422.
[28].Kario K,Kim BK,Aoki J,et al. Renal denervation in Asia:consensus statement of the Asia renal denervation consortium[J]. Hypertension,2020,75(3):590-602.
[29].Zeijen VJM,Kroon AA,van den Born BH,et al. The position of renal denervation in treatment of hypertension:an expert consensus statement[J]. Neth Heart J,2023,31(1):3-11.
[30].Barbato E,Azizi M,Schmieder RE,et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC council on hypertension and the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J]. Eur Heart J,2023,44(15):1313-1330.
[31].Lin HJ,Wang TD,Yu-Chih Chen M,et al. 2020 Consensus statement of the Taiwan Hypertension S ociety and the Taiwan Society of Cardiology on home blood pressure monitoring for the management of arterial hypertension[J]. Acta Cardiol Sin,2020,36(6):537-561.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
 SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
 FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
 CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(3):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
 ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
 ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
 HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(3):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
 ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(3):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]肖蓉雪 刘宗军.肾动脉去交感神经术治疗顽固性高血压的研究进展[J].心血管病学进展,2019,(8):1138.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
 XIAO Rongxue,LIU Zongjun.Treatment of Resistant Hypertension by Renal Denervation[J].Advances in Cardiovascular Diseases,2019,(3):1138.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
[10]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
 LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]

更新日期/Last Update: 2024-04-26